Henlius Europe

Henlius is a global biopharmaceutical company focused on offering high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. The company has successfully launched several biosimilars in China and Europe, including Hanlikon (rituximab), Hanquyou (trastuzumab), and Handayuan (adalimumab), while also advancing a robust pipeline of innovative monoclonal antibodies and combination therapies. Henlius Europe, based in Germany, serves as a strategic hub for the company's expansion into European markets, managing clinical trials, regulatory affairs, and commercial partnerships. The company utilizes an integrated platform covering the entire product lifecycle from R&D to commercial manufacturing, adhering to international GMP standards.